Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.15
USD
|
+2.94%
|
|
+3.28%
|
-3.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
762.8
|
880.7
|
402.1
|
141.8
|
205.6
|
182.5
|
-
|
-
|
Enterprise Value (EV)
1 |
762.8
|
1,110
|
587.5
|
284.6
|
205.6
|
182.5
|
182.5
|
182.5
|
P/E ratio
|
-8.24
x
|
-5.93
x
|
2.06
x
|
2.97
x
|
-1.74
x
|
-1.51
x
|
-1.75
x
|
-2.19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.82
x
|
11.9
x
|
3.6
x
|
-
|
-
|
-
|
28.1
x
|
8.11
x
|
EV / Revenue
|
6.82
x
|
11.9
x
|
3.6
x
|
-
|
-
|
-
|
28.1
x
|
8.11
x
|
EV / EBITDA
|
-
|
-8,080,963
x
|
-2,334,928
x
|
-872,769
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-3,655,915
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-7.3
x
|
17
x
|
1.66
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
54,137
|
61,652
|
62,542
|
62,730
|
62,865
|
57,943
|
-
|
-
|
Reference price
2 |
14.09
|
14.28
|
6.430
|
2.260
|
3.270
|
3.150
|
3.150
|
3.150
|
Announcement Date
|
3/2/20
|
3/1/21
|
3/1/22
|
3/13/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
111.8
|
73.81
|
111.8
|
-
|
-
|
-
|
6.5
|
22.5
|
EBITDA
|
-
|
-109
|
-172.2
|
-162.4
|
-
|
-
|
-
|
-
|
EBIT
1 |
-63.38
|
-110.6
|
-173.6
|
-163.4
|
-164.5
|
-159
|
-157.4
|
-142.4
|
Operating Margin
|
-56.69%
|
-149.84%
|
-155.33%
|
-
|
-
|
-
|
-2,421.54%
|
-632.89%
|
Earnings before Tax (EBT)
1 |
-84.49
|
-150.1
|
-191.5
|
-182
|
-174.9
|
-156.8
|
-159.6
|
-162.1
|
Net income
1 |
-84.49
|
-138.1
|
194.2
|
47.42
|
-117.8
|
-137.9
|
-134.8
|
-112
|
Net margin
|
-75.57%
|
-187.04%
|
173.78%
|
-
|
-
|
-
|
-2,073.85%
|
-498%
|
EPS
2 |
-1.710
|
-2.410
|
3.120
|
0.7600
|
-1.880
|
-2.090
|
-1.795
|
-1.440
|
Free Cash Flow
|
-
|
-
|
-110
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-98.42%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
3/1/22
|
3/13/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
30
|
31.88
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-17.94
|
-42.56
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.25
|
-42.89
|
-35.05
|
-37.44
|
-50.77
|
-40.14
|
-35.71
|
-40.9
|
-48.15
|
-39.76
|
-36.15
|
-39.1
|
-42
|
-42.25
|
Operating Margin
|
-60.84%
|
-134.53%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.7
|
-47.31
|
-33.01
|
-41.7
|
-54.79
|
-46.05
|
-39.68
|
-44.29
|
-51.66
|
-39.29
|
-33.3
|
-39
|
-41.6
|
-42.9
|
Net income
1 |
-22.7
|
280.6
|
-33.01
|
-30.85
|
-17.46
|
128.7
|
-33.7
|
-37.29
|
-37.75
|
-9.068
|
-33.65
|
-34
|
-36.3
|
-33.95
|
Net margin
|
-75.67%
|
880.24%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3600
|
4.480
|
-0.5300
|
-0.4900
|
-0.2800
|
2.050
|
-0.5400
|
-0.5900
|
-0.6000
|
-0.1500
|
-0.5600
|
-0.5250
|
-0.5350
|
-0.4950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/1/22
|
5/10/22
|
8/9/22
|
11/9/22
|
3/13/23
|
5/9/23
|
8/9/23
|
11/9/23
|
4/1/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
230
|
185
|
143
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-2.106
x
|
-1.076
x
|
-0.8791
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-110
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
120%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-63.8%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-304.4
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-1.960
|
0.3800
|
1.360
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-1.750
|
-1.760
|
-1.380
|
-
|
-
|
-
|
-
|
Capex
|
0.33
|
0.28
|
0.28
|
0.11
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.3%
|
0.38%
|
0.25%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
3/1/22
|
3/13/23
|
4/1/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -3.67% | 183M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|